The potential treatment of cannabinoids in bladder cancer is currently being studied by several research groups.
To this date, it is known that cannabinoid receptors such as CB1, CB2, and GPR55 are expressed by human bladder cells (Bakali et al., 2014).
It was shown that human bladder cancer (BC) cells RT4 and RT112 have increased expression of CB2 receptors. Cytotoxicity in bladder cancer cell lines and changes in cellular sphingolipids metabolism can be induced via activation of CB2 with the synthetic cannabinoid agonist JWH015 (Bettiga et al., 2017).
2AG plays a role in controlling inflammation and proliferation processes of bladder carcinoma cells, probably through CB receptors (Gasperi et al., 2014).